The Alzheimer Society of Ireland (ASI)’s response to the announcement of results around the TRAILBLAZER-ALZ2 Phase III clinical trial of the Alzheimer’s drug donanemab, garnered significant national Irish media coverage. Interviews with The ASI Research and Policy Manager Dr Laura O’Philbin widely featured in print and broadcast media. Dr Laura O’Philbin was also interviewed by national broadcaster RTÉ, along with Board of Directors member and Vice-Chair of the Irish Dementia Working Group Helen Rochford-Brennan (pictured, right). Results of the donanemab trial were presented by American pharmaceutical company Eli Lilly representatives at the Alzheimer’s Association International Conference in Amsterdam, in July 2023.
